Intended for U.S. healthcare professionals only.
For corporate information, please visit

Central Nervous System Products

Restoril™ (temazepam) Capsules USP, CIV 22.5 mg

This information is intended for U.S. healthcare professionals only.



Restoril™ (temazepam) Capsules USP (CIV) are indicated for the short-term treatment of insomnia (generally 7 to 10 days).



Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation.


Restoril is contraindicated in pregnant women or women who may become pregnant due to an increased risk of congenital malformations as well as risk of neonatal CNS depression.


  • Sleep disturbance may be the presenting manifestation of an underlying physical and/or psychiatric disorder. Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.
  • Behavioral changes may occur with use including aggressiveness and extroversion, bizarre behavior, agitation, hallucinations, and depersonalization.
  • Risk of the development of oversedation, dizziness, confusion, and/or ataxia increases substantially with larger doses of benzodiazepines in elderly and debilitated patients, 7.5 mg of Restoril capsules are recommended as the initial dosage for such patients.
  • Complex behaviors, such as sleep-driving, sleep-walking, etc. may occur with Restoril capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with Restoril capsules appear to increase the risk of such behaviors, as does the use of Restoril capsules at doses exceeding the maximum recommended dose.
  • Withdrawal symptoms have occurred after the abrupt discontinuation of benzodiazepines.
  • Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including Restoril capsules.
  • Restoril capsules should be administered with caution in severely depressed patients or those in whom there is any evidence of latent depression.
  • Additive effects can occur when Restoril is combined with other drugs having known hypnotic properties or CNS-depressant effects.
  • Abnormal liver function tests as well as blood dyscrasias have been reported with benzodiazepines.


  • Serious adverse reactions include complex behaviors (e.g. sleep-driving, aggressiveness) and angioedema involving the tongue, glottis or larynx, hallucinations, and agitation.
  • Common adverse reactions include drowsiness and headache.


  • Pregnancy category X. Contraindicated in pregnancy.
  • Safety and effectiveness in pediatric patients have not been established.
Description Blue Capsule
Generic Name temazepam capsules, USP
Dosage Strength 22.5 mg
Identification Code Imprinted "FOR SLEEP" on one side, other side boxed "M"® in red. Opaque blue cap imprinted "RESTORIL 22.5 mg" twice in red


NDC # Package Size Case Quantity
0406-9914-03 30's 12

For additional information on Restoril™ (temazepam) Capsules USP, CIV 22.5 mg, call Customer Service at 1.800.325.8888 or Medical Information at 1.800.778.7898.

Code: 10004671
Revised 10/2018